News and Press Releases
Tony Kouzarides, Founder of STORM Therapeutics, Awarded British Knighthood for Services to Healthcare Innovation and Delivery
Ground-breaking discoveries on the characteristics of RNA epigenetics unveiled novel targets to treat diseases 17 June 2024, Cambridge, UK - STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 17, 2024
Findings from landmark RESONATE-2 study confirm sustained survival benefit of IMBRUVICA (ibrutinib) for first-line chronic lymphocytic leukaemia treatment with up to 10 years follow-up
RESONATE-2 data presented at the 2024 European Hematology Association (EHA) Congress provide longest-term outcomes and safety data ever reported for a monotherapy BTK inhibitor, with a median PFS of 8.9...
Category: Drug Discovery
Posted: June 17, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
TALVEY (talquetamab) demonstrated highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma
24-month overall survival rate of 67% achieved with talquetamab 0.8mg/kg biweekly dosing in the phase 1/2 MonumenTAL-1 study 14 June 2024 – Beerse, Belgium – Janssen-Cilag International NV, a Johnson...
Category: Biotechnology, Drug Discovery
Posted: June 17, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
China’s Innovent holds potential to change pancreatic cancer treatment landscape with bispecific antibody IBI389, says GlobalData
14 June 2024 - China-based Innovent Biologics recently presented phase 1 study results of its first-in-class anti-CLDN18.2/CD3 bispecific antibody (IBI389) for the treatment of advanced pancreatic cancer at the 2024...
Category: Biotechnology, Pharmaceutical
Posted: June 14, 2024
New Kite Clinical Research and Real-World Evidence for Yescarta (Axicabtagene ciloleucel) Demonstrate Benefit From Earlier Lines of Treatment
Analysis shows manufacturing of axicabtagene ciloleucel in second-line treatment of relapsed/refractory large B-cell lymphoma can help reduce time from leukaepheresis to infusion vs third-line plus treatment Data builds on previous...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 14, 2024
CRISM Therapeutics Corp to continue pioneering R&D at PHTA following listing on the London Stock Exchange
11 June 2024 -- Birmingham, UK -- CRISM Therapeutics Corporation a UK-based pharmaceutical company focused on improving the clinical performance of cancer treatments for solid tumours, has raised £2.0m to...
Category: Biotechnology, Clinical Trials, Drug Delivery, Pharmaceutical
Posted: June 11, 2024
Kingston Chambers, PO Box 173, Road Town Tortola, British Virgin Islands
Oxford Drug Design and CRUK Scotland Institute awarded MRC grant funding to advance novel cancer therapeutics discovery
Collaboration to use genetically engineered mouse models to validate a new approach to cancer therapy 4 June 2024 - United Kingdom - The CRUK (Cancer Research UK) Scotland Institute and Oxford...
Category: Drug Discovery
Posted: June 10, 2024
Oxford Drug Design Lt,d Oxford Centre for Innovation, New Road, Oxford, OX1 1BY, UK
Kite Receives European Medicines Agency Approval of Safety Monitoring Variation for CAR T-Cell Therapy Portfolio
In-hospital patient monitoring for adverse events reduced from ten to seven days following CAR T-cell therapy infusion 6 June 2024 -- Stockley Park, UK -- Kite, a Gilead Company, today...
Category: Biotechnology, Other, Pharmaceutical
Posted: June 6, 2024
MediMab Biotherapeutics opens bespoke laboratory facilities, created by Kadans Science Partner, at Abingdon Science Park, UK
New CL2 wet lab purpose-built facilities delivered by Kadans Science Partner will support MediMab Biotherapeutics to identify first-in-class immuno-oncology drugs that can actively target a range of advanced and solid...
Category: Biotechnology, Manufacturing and Packing, Pharmaceutical
Posted: June 6, 2024
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumours in a Clinical Update Presented at ASCO 2024
An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for efficacy SYS6002 (CRB-701) demonstrated 44% ORR and 78% DCR in...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 5, 2024
CARVYKTI▼ (ciltacabtagene autoleucel; cilta-cel) significantly improved progression-free survival and deepened responses versus two standard therapies for patients with functional high-risk multiple myeloma
73% reduction in risk of disease progression or death seen with cilta-cel in the CARTITUDE-4 study in a subset of patients who had early relapse after initial multiple myeloma therapy...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 4, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Kite’s TECARTUS (Brexucabtagene Autoelucel) Demonstrates Sustained Overall Survival in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia
After more than four years of follow-up in the pivotal ZUMA-3 study, median overall survival was 26 months and four-year overall survival rate was 40% at 48 months Survival benefit...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: June 3, 2024
Encouraging New Data Presented on Kite’s YESCARTA (Axicabtagene Ciloleucel) for Relapsed/Refractory Central Nervous System Lymphoma
At median follow-up of 24.2 months, no apparent additional risks of adverse events related to axicabtagene ciloleucel were seen Findings also suggest efficacy trend with median progression-free survival and durability...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: June 3, 2024
TECVAYLI▼ (teclistamab) shows sustained deep and durable responses in patients with relapsed or refractory multiple myeloma
New MajesTEC-1 data show a median duration of response of 24 months, with responses deepening, including in patients who switched to biweekly dosing Separate analyses from the MajesTEC-1 and OPTec...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 3, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
DARZALEX (daratumumab)-based regimens significantly improved clinical outcomes in both transplant-eligible and -ineligible patients who are newly diagnosed with multiple myeloma
88% of transplant-eligible patients achieved a complete response or better, and 47% of patients sustained MRD-negativity for longer than one year with daratumumab subcutaneous formulation-based regimens in the phase 3...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 3, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
